Bli medlem
Bli medlem

Du är här


Diamyd Medical AB: Diamyd Medical's associated company Cellaviva withdraws new share issue

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announces that
its associated company Cellaviva has withdrawn a new share issue due
to low participation in the issue.

The issue was contingent upon a minimum subscription of MSEK 10.7 of a
maximum subscription of MSEK 11.5. Diamyd Medical's shareholding in
Cellaviva is recognized at approximately MSEK 13.5. An impairment of
the carrying amount may be required.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes
through pharmaceutical development and investments in stem cell and
medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based
Therapy (ABT) based on the exclusively licensed GAD-molecule. The
Company's licensed technologies for GABA and Gliadin have also
potential to become key pieces of the puzzle of a future solution to
prevent, treat or cure autoimmune diabetes, and also certain
inflammatory diseases. At this time six clinical studies are ongoing
with Diamyd®. Diamyd Medical is with its holdings of 45% one of the
major shareholders in the stem cell company Cellaviva AB. Stem cells
can be expected to be used in Personalized Regenerative Medicine
(PRM), for example for restoration of beta cell mass in diabetes
patients where the autoimmune component of the disease has been
arrested. Diamyd Medical also has holdings in the medtech company
Companion Medical, Inc., San Diego, USA and in the gene therapy
company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North
under the ticker DMYD B. Remium Nordic AB is the Company's Certified

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail:

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26,
Fax: +46 8 661 63 68

E-mail: Reg. no.: 556242-3797. Website:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.